WRBY vs. EYE, STAA, RXST, BLCO, LGND, NMRA, INMD, ATEC, RCUS, and OMI
Should you be buying Warby Parker stock or one of its competitors? The main competitors of Warby Parker include National Vision (EYE), STAAR Surgical (STAA), RxSight (RXST), Bausch + Lomb (BLCO), Ligand Pharmaceuticals (LGND), Neumora Therapeutics (NMRA), InMode (INMD), Alphatec (ATEC), Arcus Biosciences (RCUS), and Owens & Minor (OMI). These companies are all part of the "medical" sector.
Warby Parker (NYSE:WRBY) and National Vision (NASDAQ:EYE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and analyst recommendations.
Warby Parker has higher earnings, but lower revenue than National Vision. Warby Parker is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.
In the previous week, Warby Parker had 2 more articles in the media than National Vision. MarketBeat recorded 15 mentions for Warby Parker and 13 mentions for National Vision. National Vision's average media sentiment score of 1.03 beat Warby Parker's score of 0.39 indicating that National Vision is being referred to more favorably in the news media.
93.2% of Warby Parker shares are owned by institutional investors. 26.9% of Warby Parker shares are owned by company insiders. Comparatively, 2.1% of National Vision shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
National Vision received 229 more outperform votes than Warby Parker when rated by MarketBeat users. Likewise, 65.89% of users gave National Vision an outperform vote while only 32.88% of users gave Warby Parker an outperform vote.
National Vision has a net margin of -3.44% compared to Warby Parker's net margin of -7.89%. National Vision's return on equity of 3.47% beat Warby Parker's return on equity.
Warby Parker currently has a consensus target price of $16.50, suggesting a potential upside of 0.67%. National Vision has a consensus target price of $19.60, suggesting a potential upside of 21.74%. Given National Vision's higher probable upside, analysts plainly believe National Vision is more favorable than Warby Parker.
Warby Parker has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500. Comparatively, National Vision has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.
Summary
Warby Parker and National Vision tied by winning 9 of the 18 factors compared between the two stocks.
Get Warby Parker News Delivered to You Automatically
Sign up to receive the latest news and ratings for WRBY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WRBY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Warby Parker Competitors List
Related Companies and Tools
